Arch Biopartners Stock Price Prediction
| ARCH Stock | CAD 1.95 0.01 0.51% |
Oversold Vs Overbought
56
Oversold | Overbought |
Quarterly Earnings Growth (0.69) | Quarterly Revenue Growth (0.14) |
Using Arch Biopartners hype-based prediction, you can estimate the value of Arch Biopartners from the perspective of Arch Biopartners response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Arch Biopartners to buy its stock at a price that has no basis in reality. In that case, they are not buying Arch because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Arch Biopartners after-hype prediction price | CAD 1.93 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Arch |
Arch Biopartners After-Hype Price Prediction Density Analysis
As far as predicting the price of Arch Biopartners at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Arch Biopartners or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Arch Biopartners, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Arch Biopartners Estimiated After-Hype Price Volatility
In the context of predicting Arch Biopartners' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Arch Biopartners' historical news coverage. Arch Biopartners' after-hype downside and upside margins for the prediction period are 0.10 and 4.62, respectively. We have considered Arch Biopartners' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Arch Biopartners is risky at this time. Analysis and calculation of next after-hype price of Arch Biopartners is based on 3 months time horizon.
Arch Biopartners Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Arch Biopartners is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arch Biopartners backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Arch Biopartners, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.54 | 2.69 | 0.02 | 0.04 | 1 Events / Month | 1 Events / Month | Very soon |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.95 | 1.93 | 1.03 |
|
Arch Biopartners Hype Timeline
Arch Biopartners is presently traded for 1.95on TSX Venture Exchange of Canada. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of -0.04. Arch is forecasted to decline in value after the next headline, with the price expected to drop to 1.93. The average volatility of media hype impact on the company price is over 100%. The price drop on the next news is expected to be -1.03%, whereas the daily expected return is presently at 0.54%. The volatility of related hype on Arch Biopartners is about 3842.86%, with the expected price after the next announcement by competition of 1.91. About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.03. Arch Biopartners last dividend was issued on the 13th of September 2000. The entity had 1:3 split on the 25th of November 2003. Assuming the 90 days trading horizon the next forecasted press release will be very soon. Check out Arch Biopartners Basic Forecasting Models to cross-verify your projections.Arch Biopartners Related Hype Analysis
Having access to credible news sources related to Arch Biopartners' direct competition is more important than ever and may enhance your ability to predict Arch Biopartners' future price movements. Getting to know how Arch Biopartners' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Arch Biopartners may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| NGEN | NervGen Pharma Corp | (0.01) | 1 per month | 4.41 | 0.01 | 6.15 | (5.84) | 32.94 | |
| NSCI | Nanalysis Scientific Corp | 0.00 | 2 per month | 0.00 | (0.10) | 5.26 | (5.41) | 19.87 | |
| PINK | Perimeter Medical Imaging | (0.03) | 3 per month | 6.15 | 0.08 | 13.21 | (10.00) | 32.13 | |
| MDNA | Medicenna Therapeutics Corp | (0.24) | 2 per month | 0.00 | (0.05) | 7.66 | (8.26) | 27.82 |
Arch Biopartners Additional Predictive Modules
Most predictive techniques to examine Arch price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Arch using various technical indicators. When you analyze Arch charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Arch Biopartners Predictive Indicators
The successful prediction of Arch Biopartners stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Arch Biopartners, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Arch Biopartners based on analysis of Arch Biopartners hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Arch Biopartners's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Arch Biopartners's related companies. | 2021 | 2023 | 2024 (projected) | Graham Number | 0.17 | 0.23 | 0.3 | Receivables Turnover | 11.06 | 20.06 | 21.06 |
Story Coverage note for Arch Biopartners
The number of cover stories for Arch Biopartners depends on current market conditions and Arch Biopartners' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Arch Biopartners is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Arch Biopartners' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Arch Biopartners Short Properties
Arch Biopartners' future price predictability will typically decrease when Arch Biopartners' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Arch Biopartners often depends not only on the future outlook of the potential Arch Biopartners' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arch Biopartners' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62.5 M | |
| Cash And Short Term Investments | 831.3 K |
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.